The role of Bladder EpiCheck <sup>®</sup> test in predicting residual tumor after transurethral resection of bladder cancer: Results from a pilot study
may help identify patients without residual tumor and potentially avoid unnecessary Re-TURB. Larger prospective multicenter studies are required to confirm these findings.
Authors
- M Manfredi
- Luca Orecchia (ORCID: https://orcid.org/0000-0001-8376-5380)
- Anastasios D. Asimakopoulos (ORCID: https://orcid.org/0000-0002-7230-579X)
- Patrizio Pacini
- Serena Lavorgna (ORCID: https://orcid.org/0000-0001-8812-2325)
- Roberto Miano (ORCID: https://orcid.org/0000-0003-2445-1204)
- Serena Travaglini (ORCID: https://orcid.org/0000-0002-5411-1502)
- Simone Pletto
- Nunzia Abbate
- Valeria Feliciangeli (ORCID: https://orcid.org/0009-0005-9933-8259)
- Enrico Finazzi Agrò
- Francesco Porpiglia
Institutions
- University of Rome Tor Vergata (IT)
- Nini Hospital (LB)
- Policlinico Tor Vergata (IT)
- University of Turin (IT)
Publication Details
- Journal
- Urologia Journal
- Published
- 2026-04-16
- DOI
- https://doi.org/10.1177/03915603261440213
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00